TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06075810: A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Sponsor: MBQ Pharma · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,864,168

Rescue Site Savings

+$2,544,696

Unlock Full NCT06075810 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06075810 Rescue Dossier →